| Objective To analyze the safety and efficacy of 3 doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients with chronic hepatitis B virus (HBV) infection. Methods?A total of 107 patients with chronic HBV infection who attended the Fifth Medical Center of PLA General Hospital from October 2021 to August 2022 and voluntarily received SARS-CoV-2 vaccine were followed up at the 0 (baseline), 1, 2, 4, 7 and 8 months, and their blood routine, blood biochemistry and coagulation were tested regularly. The safety of the vaccine was evaluated by recording the adverse events within 28 days and the dynamic changes of laboratory indexes after each dose of SARS-CoV-2 vaccine of patients with chronic HBV infection. During the follow-up, plasma samples were taken to detect the neutralizing antibody titers to evaluate its effectiveness, and the possible influencing factors of antibody titer were analyzed. Results?After three doses of SARS-CoV-2 vaccine, the incidence of adverse events in patients with chronic HBV infection was 22.43% (24/107), 19.79% (19/96) and 16.67% (12/72) respectively, and the most common adverse event was pain at the injection site. After vaccination, the chemical and virological indexes did not deteriorate. After each dose of SARS-CoV-2 vaccine, the titer of neutralizing antibody increased significantly (P＜0.05), and then decreased gradually with time. The age of the subjects in antibody positive group was lower than that in negative group [(42.27±9.40）vs. 48.00 (43.00, 53.50), P=0.040]. Conclusions?SARS-CoV-2 vaccine is safe and effective for patients with chronic HBV infection.There was a low incidence of adverse reactions and no vaccine-related serious adverse events. Patients with chronic HBV infection have the highest neutralizing antibody titers after receiving a booster dose. Age affects antibody titers after vaccination in people with chronic HBV infection. |